Total Payments
$5,931
2024 Payments
$419.48
Companies
40
Transactions
342
Medicare Patients
11,213
Medicare Billing
$1.5M
Payment Breakdown by Category
Food & Beverage$5,859 (98.8%)
Education$55.07 (0.9%)
Other$17.07 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,859 | 334 | 98.8% |
| Education | $55.07 | 7 | 0.9% |
| Entertainment | $17.07 | 1 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $1,049 | 44 | $0 (2024) |
| GlaxoSmithKline, LLC. | $450.13 | 24 | $0 (2024) |
| Lilly USA, LLC | $424.53 | 39 | $0 (2023) |
| PFIZER INC. | $417.91 | 34 | $0 (2024) |
| ABBVIE INC. | $387.46 | 20 | $0 (2024) |
| Amgen Inc. | $387.08 | 25 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $293.75 | 17 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $291.56 | 16 | $0 (2024) |
| Astellas Pharma US Inc | $261.82 | 10 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $227.22 | 11 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $419.48 | 21 | GlaxoSmithKline, LLC. ($97.38) |
| 2023 | $653.52 | 33 | Novo Nordisk Inc ($187.64) |
| 2022 | $520.85 | 29 | ABBVIE INC. ($235.37) |
| 2021 | $559.05 | 34 | Boehringer Ingelheim Pharmaceuticals, Inc. ($84.44) |
| 2020 | $345.07 | 21 | GlaxoSmithKline, LLC. ($72.54) |
| 2019 | $734.17 | 38 | Novo Nordisk Inc ($118.60) |
| 2018 | $1,118 | 63 | Novo Nordisk Inc ($323.11) |
| 2017 | $1,580 | 103 | Lilly USA, LLC ($279.73) |
All Payment Transactions
342 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/25/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $15.39 | General |
| Category: Gastroenterology | ||||||
| 10/30/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $34.37 | General |
| Category: NEUROSCIENCE | ||||||
| 10/22/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $20.40 | General |
| Category: RESPIRATORY | ||||||
| 10/15/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $28.26 | General |
| 09/17/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $17.35 | General |
| Category: NEUROLOGY | ||||||
| 07/17/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $28.15 | General |
| Category: RESPIRATORY | ||||||
| 07/16/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $21.52 | General |
| Category: Biological | ||||||
| 06/27/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $15.21 | General |
| Category: Bone Health | ||||||
| 05/28/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $20.43 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 05/21/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $15.48 | General |
| Category: RESPIRATORY | ||||||
| 05/17/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $13.67 | General |
| Category: Respiratory | ||||||
| 04/11/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $15.66 | General |
| 03/29/2024 | Saluda Medical Americas, Inc. | Evoke (Device) | Food and Beverage | In-kind items and services | $18.38 | General |
| Category: Spinal Cord Stimulator | ||||||
| 03/29/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $14.42 | General |
| Category: RESPIRATORY | ||||||
| 03/21/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $28.71 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 03/15/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $29.05 | General |
| Category: Biological | ||||||
| 02/27/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $19.71 | General |
| Category: Diabetes | ||||||
| 02/14/2024 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Food and Beverage | In-kind items and services | $18.93 | General |
| Category: VACCINES | ||||||
| 02/13/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $13.66 | General |
| Category: Obesity | ||||||
| 02/06/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $14.00 | General |
| Category: Bone Health | ||||||
| 01/11/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $16.73 | General |
| Category: Oncology | ||||||
| 11/30/2023 | Novo Nordisk Inc | Rybelsus (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: Diabetes | ||||||
| 11/01/2023 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $14.41 | General |
| Category: RESPIRATORY | ||||||
| 10/24/2023 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Food and Beverage | In-kind items and services | $20.64 | General |
| Category: VACCINES | ||||||
| 10/05/2023 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $14.99 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 29 | 3,091 | 8,202 | $1.6M | $485,125 |
| 2022 | 25 | 3,015 | 6,692 | $1.3M | $389,157 |
| 2021 | 27 | 2,740 | 5,357 | $1.1M | $320,614 |
| 2020 | 18 | 2,367 | 6,268 | $1.1M | $346,627 |
Total Patients
11,213
Total Services
26,519
Medicare Billing
$1.5M
Procedure Codes
99
All Medicare Procedures & Services
99 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 699 | 1,966 | $627,154 | $173,718 | 27.7% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 253 | 1,865 | $186,500 | $85,810 | 46.0% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 246 | 1,618 | $242,700 | $58,677 | 24.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 438 | 438 | $142,350 | $54,632 | 38.4% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 200 | 266 | $83,381 | $22,399 | 26.9% |
| 93229 | Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | Office | 2023 | 23 | 25 | $54,175 | $16,028 | 29.6% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 137 | 366 | $33,672 | $12,724 | 37.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 145 | 182 | $40,950 | $11,566 | 28.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 75 | 75 | $30,975 | $7,521 | 24.3% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 101 | 110 | $24,428 | $6,677 | 27.3% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 33 | 36 | $18,252 | $5,661 | 31.0% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 21 | 26 | $17,784 | $5,502 | 30.9% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 44 | 111 | $13,653 | $4,106 | 30.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 27 | 30 | $13,380 | $3,894 | 29.1% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 80 | 220 | $12,540 | $3,454 | 27.5% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 109 | 109 | $5,450 | $1,938 | 35.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 44 | 44 | $6,072 | $1,814 | 29.9% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2023 | 11 | 11 | $4,565 | $1,759 | 38.5% |
| G0506 | Comprehensive assessment of and care planning for patients requiring chronic care management services (list separately in addition to primary monthly care management service) | Office | 2023 | 31 | 31 | $4,681 | $1,473 | 31.5% |
| 99453 | Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | Office | 2023 | 88 | 93 | $4,278 | $1,249 | 29.2% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2023 | 21 | 35 | $3,500 | $1,065 | 30.4% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 22 | 23 | $2,967 | $924.60 | 31.2% |
| 93224 | Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | Office | 2023 | 14 | 15 | $2,775 | $795.15 | 28.7% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 63 | 67 | $2,345 | $699.93 | 29.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 35 | 53 | $1,855 | $533.12 | 28.7% |
About Dr. Jerrelle Copeland, M.D
Dr. Jerrelle Copeland, M.D is a Internal Medicine healthcare provider based in Gold Canyon, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/21/2005. The National Provider Identifier (NPI) number assigned to this provider is 1790784643.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jerrelle Copeland, M.D has received a total of $5,931 in payments from pharmaceutical and medical device companies, with $419.48 received in 2024. These payments were reported across 342 transactions from 40 companies. The most common payment nature is "Food and Beverage" ($5,859).
As a Medicare-enrolled provider, Copeland has provided services to 11,213 Medicare beneficiaries, totaling 26,519 services with total Medicare billing of $1.5M. Data is available for 4 years (2020–2023), covering 99 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Gold Canyon, AZ
- Active Since 07/21/2005
- Last Updated 02/02/2026
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1790784643
Products in Payments
- TRELEGY ELLIPTA (Drug) $321.10
- XARELTO (Drug) $227.22
- TRULICITY (Drug) $220.20
- EVENITY (Biological) $211.68
- Victoza (Drug) $206.72
- FARXIGA (Drug) $204.69
- Myrbetriq (Drug) $191.89
- ENTRESTO (Drug) $178.60
- UBRELVY (Drug) $173.10
- JARDIANCE (Drug) $162.25
- Vascepa (Drug) $160.54
- Tresiba (Drug) $152.47
- CHANTIX (Drug) $141.74
- Rybelsus (Drug) $120.10
- TRADJENTA (Drug) $118.83
- Prolia (Biological) $116.49
- Ozempic (Drug) $115.17
- Trintellix (Drug) $114.48
- XIFAXAN (Drug) $107.14
- LYRICA (Drug) $106.03
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.